Verneuil Vanina De Sells 4,445 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 4,445 shares of the stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $7.45, for a total transaction of $33,115.25. Following the completion of the sale, the executive vice president owned 129,799 shares of the company’s stock, valued at approximately $967,002.55. The trade was a 3.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Vir Biotechnology Trading Up 27.7%

VIR traded up $2.06 on Tuesday, hitting $9.49. 38,240,174 shares of the stock traded hands, compared to its average volume of 1,972,225. The business has a fifty day moving average price of $6.80 and a two-hundred day moving average price of $5.99. The firm has a market capitalization of $1.32 billion, a PE ratio of -3.00 and a beta of 1.69. Vir Biotechnology, Inc. has a 52 week low of $4.16 and a 52 week high of $10.29.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.11. The company had revenue of $64.07 million during the quarter, compared to the consensus estimate of $19.91 million. Vir Biotechnology had a negative return on equity of 47.14% and a negative net margin of 638.88%.The company’s quarterly revenue was up 417.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.76) EPS. On average, equities research analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Vir Biotechnology News Roundup

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas strategic collaboration: Vir announced a global co‑development/co‑commercialization collaboration with Astellas for prostate cancer candidate VIR‑5500 that includes $335M upfront/near‑term payments, up to $1.37B in additional milestones, a 50/50 U.S. profit/loss split, Astellas leading U.S. commercialization and ex‑U.S. rights, plus tiered double‑digit ex‑U.S. royalties — a major de‑risking and validation event for the program. Read More.
• Positive Sentiment: Encouraging Phase 1 VIR‑5500 data: Updated trial results show a favorable safety profile and meaningful activity (reported ORR ~45% at higher doses in later cohorts), supporting the value of the asset and underpinning the Astellas deal. Read More.
• Positive Sentiment: Quarterly beat and strong revenue growth: Q4 EPS of ($0.31) beat estimates and revenue of $64.1M significantly exceeded the consensus (~$19.9M), with revenue up ~418% year‑over‑year — evidence of commercial traction and stronger near‑term financial performance. Read More.
• Positive Sentiment: Analyst upgrade: Needham raised its price target to $18 and maintained a buy rating, adding institutional validation and support for higher upside expectations. Read More.
• Neutral Sentiment: Broad media coverage and analyst commentary: Multiple outlets (Forbes, Seeking Alpha, MSN) are highlighting the deal, data and earnings beat — amplifying attention and trading volume but not adding new fundamentals. Read More.
• Neutral Sentiment: Company disclosures and materials: Earnings call transcript and slide deck provide more color on pipeline prioritization (HDV, oncology) and capital deployment plans. Read More.
• Negative Sentiment: Proposed public offering: Vir filed to sell additional shares, which can be dilutive and weigh on near‑term share price despite the cash proceeds. Read More.
• Negative Sentiment: Ongoing losses and wide negative margins: The company reported a large 2025 net loss (and very negative margins), so long‑term value depends on successful development/commercial execution and milestone/cash management. Read More.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of VIR. ARCH Venture Management LLC bought a new stake in Vir Biotechnology during the 2nd quarter worth approximately $65,100,000. GSK plc acquired a new position in Vir Biotechnology in the fourth quarter worth $51,562,000. Balyasny Asset Management L.P. bought a new stake in shares of Vir Biotechnology during the fourth quarter worth $8,252,000. State Street Corp increased its stake in shares of Vir Biotechnology by 18.9% in the fourth quarter. State Street Corp now owns 6,229,555 shares of the company’s stock valued at $37,564,000 after buying an additional 988,262 shares in the last quarter. Finally, Millennium Management LLC increased its stake in shares of Vir Biotechnology by 129.2% in the third quarter. Millennium Management LLC now owns 1,396,504 shares of the company’s stock valued at $7,974,000 after buying an additional 787,212 shares in the last quarter. 65.32% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on VIR. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. Raymond James Financial raised shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price target for the company in a research report on Tuesday. Morgan Stanley raised their price target on shares of Vir Biotechnology from $20.00 to $24.00 and gave the stock an “overweight” rating in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Vir Biotechnology in a research note on Tuesday, December 30th. Finally, Barclays reissued an “overweight” rating and issued a $30.00 target price on shares of Vir Biotechnology in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Vir Biotechnology has an average rating of “Moderate Buy” and a consensus target price of $19.88.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.